Evidence map›Paper›PMID 36046608›Full record

ArticleFrontiers in molecular biosciences2022

Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants.

Adrianne L Gelbach, Fuming Zhang, Seok-Joon Kwon, John T Bates, Andrew P Farmer, Jonathan S Dordick, Chunyu Wang, Robert J Linhardt

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Proteoglycans: a common portal for SARS-CoV-2 and extracellular vesicle uptake.American journal of physiology. Cell physiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adrianne L GelbachDepartment of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Fuming ZhangDepartment of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Seok-Joon KwonDepartment of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
John T BatesDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS, United States.
Andrew P FarmerDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, United States.
Jonathan S DordickDepartment of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Chunyu WangDepartment of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Robert J LinhardtDepartment of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.

Funding

Heparan Sulfate 3-O-Sulfation in Transcellular Propagation of Tauopathy in Alzheimer's DiseaseRF1AG069039 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI LINHARDT, ROBERT J, LIU, JIAN · 2020 to 2020
$2.6M
The Alzheimer's Disease Clinical and Translational Research (ADCTR) Training ProgramT32AG057464 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI WANG, CHUNYU · 2017 to 2021
$1.6M
Predoctoral Training Program for Alzheimer’s Disease at the Interface of Data Science, Engineering and BiologyT32AG078123 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI Chunyu Wang · 2023 to 2026
$974k
NIA NIH HHS RF1 AG069039NIA NIH HHS T32 AG057464NIA NIH HHS T32 AG078123
6 · The paper itself

Abstract

Heparan sulfate (HS) acts as a co-receptor of angiotensin-converting enzyme 2 (ACE2) by interacting with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein (SGP) facilitating host cell entry of SARS-CoV-2 virus. Heparin, a highly sulfated version of heparan sulfate (HS), interacts with a variety of proteins playing key roles in many physiological and pathological processes. In this study, SARS-CoV-2 SGP receptor binding domain (RBD) wild type (WT), Delta and Omicron variants were expressed in Expi293F cells and used in the kinetic and structural analysis on their interactions with heparin. Surface plasmon resonance (SPR) analysis showed the binding kinetics of SGP RBD from WT and Delta variants were very similar while Omicron variant SGP showed a much higher association rate. The SGP from Delta and Omicron showed higher affinity (

Indexed as

heparan sulfateheparinSARS-CoV-2spike protein RBDsurface plasmon resonance

Identifiers

PMID36046608
PMCPMC9420978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.